top of page
Search

Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibit

  • May 27, 2023
  • 1 min read

August 2021


Sierra Oncology has acquired an exclusive global license from AstraZeneca for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study in the first half of 2022 to examine the combination of AZD5153 with momelotinib in myelofibrosis patients. Momelotinib is a selective JAK1, JAK2, and ACVR1/ALK2 inhibitor currently being investigated for the treatment of myelofibrosis.


The combination of JAK inhibition and BET inhibition has shown promise for myelofibrosis treatment. Sierra Oncology aims to leverage this combination to provide improved outcomes for patients. The agreement involves upfront and milestone payments to AstraZeneca, and Sierra will be responsible for the Phase 2 trial execution and global development and commercialization activities.


Link to the press release here.


Comments

Rated 0 out of 5 stars.
No ratings yet
Add a rating
Global MPN Scientific Foundation Logo

Contact

Avenida Josep Tarradellas 157, 5o 2a - Barcelona, 08029 - Spain

Email:
info@gmpnsf.org

Follow

Sign up to get the latest news on our activities and MPN news.

Thanks for subscribing!

CONTENT TRANSLATION DISCLAIMER

​

Please note that this website uses AI to automatically translate its content to other languages, to help people to better understand the content that we originally publish in English. While we have made every effort to ensure the accuracy of the translation, there may be some mistakes or inaccuracies. We apologize for any errors and suggest visiting the original text in English for the most accurate information.

​

MEDICAL DISCLAIMER

​

Information on this website is provided for informational purposes only and is not intended as a substitute for the advice provided by your physician or other healthcare professional. You should not use the information on this website for diagnosing or treating a health problem or disease, or prescribing any medication or other treatment.

 

Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment. Nothing contained on this website is intended to be for medical diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare provider. Should you have any healthcare-related questions, please call or see your physician or other qualified healthcare provider promptly. Always consult with your physician or other qualified healthcare provider before embarking on a new treatment, diet, or fitness program. 

​

This website does not recommend self-management of health issues. Information obtained by using this website is not exhaustive and does not cover all diseases, ailments, physical conditions, or their treatment. Should you have any healthcare-related questions, please call or see your physician or other qualified healthcare provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here.

bottom of page